Research progress of cetuximab in the treatment of head and neck squamous cell carcinoma

VernacularTitle:西妥昔单抗治疗头颈鳞状细胞癌的研究进展
Author: Yuzhi LIU ¹ ; Hongwei LIU
Author Information

1. 辽宁中医药大学第一临床学院,辽宁沈阳 110847
Keywords: cetuximab; head and neck squamous cell carcinoma; locally advanced head and neck squamous cell carcinomas; recurrent/metastatic head and neck squamous cell carcinomas
From: Journal of Shenyang Medical College 2024;26(2):193-199
CountryChina
Language:Chinese
Abstract: Head and neck squamous cell carcinoma(HNSCC)is the most common type of head and neck cancer,with poor prognosis and poor quality of life.In recent years,with the rapid development of targeted therapy,cetuximab has been widely used in clinical practice as the molecular targeted drug approved by the Food and Drug Administration(FDA)for the treatment of HNSCC.For locally advanced and recurrent/distant metastatic HNSCC,cetuximab combined with radiotherapy,chemotherapy,concurrent chemoradiotherapy,or combined radiotherapy after induction chemotherapy have shown great advantages.The treatment of HNSCC has now entered the era of immunity.Several clinical trials data have shown that cetuximab combined with immunotherapy or new targeted drugs have significant effects on HNSCC.In the future,scholars need to further explore immunotherapy to provide better choices for patients with HNSCC.This article reviews the mechanism of action of cetuximab and its research progress in the treatment of HNSCC.